DiaSorin SpA
MIL:DIA

Watchlist Manager
DiaSorin SpA Logo
DiaSorin SpA
MIL:DIA
Watchlist
Price: 100.15 EUR -0.1% Market Closed
Market Cap: 5.6B EUR
Have any thoughts about
DiaSorin SpA?
Write Note

DiaSorin SpA
Free Cash Flow

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

DiaSorin SpA
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
DiaSorin SpA
MIL:DIA
Free Cash Flow
€189.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
El En SpA
MIL:ELN
Free Cash Flow
€61.7m
CAGR 3-Years
-5%
CAGR 5-Years
17%
CAGR 10-Years
N/A
No Stocks Found

DiaSorin SpA
Glance View

Market Cap
5.3B EUR
Industry
Health Care

In the heart of the global healthcare landscape, DiaSorin SpA stands as a testament to innovation and precision in the field of biotechnology. Founded in 1968 in Italy, the company built its reputation on developing and producing diagnostic tests that help identify and monitor diseases. With a primary focus on immunodiagnostic and molecular diagnostic products, DiaSorin excels in creating high-quality, reliable solutions that clinicians and labs around the world depend on. Their product portfolio ranges widely, covering infectious diseases, oncology, endocrinology, and more. By leveraging cutting-edge research and development processes, DiaSorin not only prioritizes accuracy and efficiency in its testing solutions but also adapts to the ever-evolving demands of the medical world, cementing its role as a leader in diagnostic innovation. From a business perspective, DiaSorin's revenue streams are deeply intertwined with its prowess in developing proprietary testing technologies, including both instruments and consumables. The company operates with a dual-channel business model where it sells diagnostic machines to laboratories, hospitals, and clinics while simultaneously providing the reagents and kits necessary for these machines' continuous operation. This approach ensures not only a sale of sophisticated equipment but also a recurring revenue stream from the consumables needed for diagnostics. With a strategic emphasis on research and partnerships, DiaSorin has expanded its reach globally, ensuring its products meet diverse regional healthcare requirements. Through a combination of robust product offerings and strategic global expansion, DiaSorin continues to thrive and maintain its position as a pivotal contributor to the field of diagnostic medicine.

DIA Intrinsic Value
94.5 EUR
Overvaluation 6%
Intrinsic Value
Price

See Also

What is DiaSorin SpA's Free Cash Flow?
Free Cash Flow
189.7m EUR

Based on the financial report for Sep 30, 2024, DiaSorin SpA's Free Cash Flow amounts to 189.7m EUR.

Back to Top